Journal of
Biomedical and Biological Sciences

Review Article Open Access

Chronic Obstructive Pulmonary Disease: Definition, Risk Factors, Pathophysiology and Management

Gudisa Bereda[1*]

[1]Department of Pharmacy, Negelle Health Science College, Guji, Ethiopia.

[*]**Corresponding Author:** Bereda G, Department of Pharmacy, Negelle Health Science College, Guji, Ethiopia. Email: gudisabareda95@gmail.com

Citation: Bereda G. Chronic Obstructive Pulmonary Disease: Definition, Risk Factors, Pathophysiology and Management. Journal of Biomedical and Biological Sciences. 2022;2(1):1-12.

Received Date: 11th February, 2022 **Accepted Date: 17th March, 2022** **Published Date: 27th March, 2022**

Abstract

Coinciding to the delineation of the European Respiratory Society, chronic obstructive pulmonary disease is a disorder described by decreased maximum expiratory flow and slow forced emptying of the lungs owing to diversifying combinations of diseases of the airways and emphysema. COPD sequences from the exposure of vulnerable individuals to a variety of inhaled noxious gases and particles. Exposure to tobacco smoke is by far the consummate significant peril factor for chronic obstructive pulmonary disease, and the intensity and duration of exposure correlate with the severity of failures. The inflammatory procedure in chronic obstructive pulmonary disease is varying from that in asthma. Expiratory flow limitation is the pathophysiological hallmark of chronic obstructive pulmonary disease. The intentions of chronic obstructive pulmonary disease treatment involve inhibition of disease development; decrement of the frequency and severity of exacerbations; relief of dyspnea and other respiratory symptoms; controlling exposure to peril factors, ameliorating the exercise tolerance; prevent symptoms and recurrent exacerbations. Smoking cessation slows the smoking-induced raised rate of decrement in lung function, ameliorates health and decreases mortality, irrespective of the severity of the pulmonary failures in patients with chronic obstructive pulmonary disease. Regular management with long-acting bronchodilators is the pivotal of therapy in symptomatic patients with moderate to severe chronic obstructive pulmonary disease.

Keywords: Chronic Obstructive Pulmonary Disease; Definition; Management; Pathophysiology; Risk Factors

Abbreviations: AEs: Acute exacerbations; AECOPD: Acute exacerbation of chronic obstructive pulmonary disease; COPD: Chronic obstructive pulmonary disease; CV: Cardiovascular; ERS: European Respiratory Society; LABA: Long-acting beta2-agonist; LAMA: Long-acting muscarinic antagonist; MDI: Metered-dose inhalers; MEF: Maximum expiratory flow; MRC: Medical Research Council; PRN: As needed; Rx: Treatment; SAMA: Short-acting muscarinic antagonist

Journal of
Biomedical and Biological Sciences

Review Article Open Access

Introduction

Coinciding to the delineation of the European Respiratory Society, COPD is a disorder described by de-escalated MEF and slow forced emptying of the lungs owing to different combinations of diseases of the airways and emphysema [1]. COPD is an advancing global epidemic that is specifically significant in developing countries. Currently morbidity and mortality from COPD will increases as population's age and mortality from CV and infectious diseases falls. Although smoking the cigarette is the most common antecedent of COPD in developed countries, COPD is also seen in non-smokers, specifically in developing countries, yet extremely fewer is known about this form of COPD. COPD is initially described by the availability of airflow limitation sequencing from inflammation and remodelling of small airways and is frequently consociated with lung parenchymal diminishing or emphysema. It is highly realized that COPD prolongs besides the lung and that multiple patients have various systemic sign and symptoms that can more rupturing functional capability and health-related QOL [2]. These are frequently described by partially reversible expiratory airflow limitation. Furthermore, certain have suggested that distinctive phenotypes with systemic inflammation and chronic mucus hypersecretion should also be involved under the term COPD [3, 4]. COPD rarely happens before age forty-five, rarely happens in a non-smoker, lung function never returns to normal, can happen with asthma. The airway component consists chiefly of de-escalated luminal diameters owing to several combinations of escalated wall thickening, escalated intraluminal mucus, and alters in the lining fluid of the small airways. Emphysema is delineated structurally by perpetual, rupturing increment of airspaces distal to the terminal bronchioles without known fibrosis. Failure of alveolar binds to the airway outside the edge of surface gives to airway stenosis. Chronic bronchitis is delineated by the availability of chronic or recurrent escalates in bronchial secretions adequate to antecedent expectoration. The syntheses are available on consummate days for a minimum of 3 months a year, for at least two consecutive years, and can't be rendered to distinctive pulmonary or cardiac antecedents [5].

The magnitude of COPD in the general population is evaluated to be, one percent across entire ages increasing abruptly to ten percent amongst those aged of forty years [6]. COPD influences greater than 200 million people worldwide and is the 4th leading cause of death [7, 8]. In adults aged eighteen to forty-four, three-point two percent of the population has been diagnosed with COPD. In adult's ages sixty-five and above, 11.6% have been diagnosed with COPD. White adults have the most rate of COPD (6.3%). 6.1% of black adults and 4.3% of Hispanic adults have COPD.

Classification of Severity

The current GOLD guidelines delineate airflow obstruction as FEV1/FVC <0.7, and categorize COPD into 4 stages depending on the post-bronchodilator FEV1. These stages are: stage 1 or mild COPD with an FEV1 >80% predicted; stage 2 or moderate COPD with FEV1 between 50% and 80% predicted; stage 3 or severe COPD with FEV1 between 30% and 50% predicted; and stage 4 or very severe COPD with FEV1 either <30% predicted, or <50% predicted combined with hypoxaemia (partial pressure of oxygen in arterial blood [PaO2] <60 mmHg) with or without hypercarbia (partial pressure of carbon dioxide in arterial blood [PaCO2] >50 mmHg). These updated guidelines removed the previously categorized stage 0, which included patients who were at peril of advancing COPD but did not have evidence of airflow obstruction [3, 9].

Risk Factors

COPD sequences from the exposure of vulnerable individuals to a several of inhaled noxious gases and particles. Exposure to tobacco smoke is byfar the consummate significant peril factor for COPD, and the intensity and duration of exposure correlate with the severity of failure. Indoor air pollution from biomass fuels and wood burning are also implicated in antecedent COPD, specifically in women in developing countries. Outdoor air pollution has not been implicated as a peril factor for COPD, but it does escalate the rate of emergency room visits for COPD exacerbations, specifically in the geriatrics. Distinctive inhaled particles and gases could also be peril factors. Several

Journal of
Biomedical and Biological Sciences

Review Article Open Access

of genetic factors perhaps play a function in the host-environment interaction, but solely the function of homozygous mutations of the a1-antitrypsin gene in causing COPD is well settled. Genetic leads might describe why not all smokers advance COPD. Women perhaps also have a greater peril of advancing serious, early-onset COPD despite having identical exposures to men. The etiology for this gender-based variety in vulnerability is not entirely clear. Lower socioeconomic status during childhood perhaps escalates the peril of advancing COPD in adult life, but this perhaps be owing to the escalated peril of exposure to particles and gases distinctive than tobacco smoke under those situations [3].

Pathophysiology

A variety mechanistic concept has been implicated in the pathogenesis of COPD. Primarily, the cornerstone of COPD is advancement of exacerbated chronic inflammation in the lung in reaction to inhalation of smoking cigarette analogized with smokers with no lung disease. Risk factors involving genetic vulnerability, epigenetic alters and oxidative stress render by increasing inflammation initiated by cigarette smoking. Secondly, patients with scarcity of α1-antitrypsin, the chief suppressor of neutrophil elastase, advance emphysema early in life, due to an unbalance between proteinases and antiproteases influencing to a net escalate in proteolytic activity. Third, an unbalance between oxidizing agents and substance prevents harmful chemical reaction in the lungs of patients with COPD, sequencing in overmuch the process of oxidizing stress, not solely increases airway inflammation in smokers, but also initiates cell death of relating to the structure cells in the lung (chiefly alveolar epithelial and endothelial cells). Rupturing of equilibrate between cell death and build up again of relating to the structure cells in the lung give to the decrement of alveolar septa, influencing to emphysema. Furthermore, age-related alters and cellular senescence more injury tissue mends in reaction to repetitive cigarette smoke-induced damage of the lungs. Autoimmunity has been announced as a delay causing of disease outcome in the progressive course of the disease. The variety mechanisms do not function separately in the development of disease of COPD, but are highly intercalated. Procedure of oxidizing stress, for instance, renders to the unbalance between proteinase and antiprotease by make inactivate antiproteases, although a surplus of apoptotic cells influences to 2ndry necrosis and can exacerbate continuing pulmonary inflammation [7, 10-12]. The inflammatory procedure in COPD is distinctive from that in asthma. Expiratory flow shortcoming is the pathophysiological pivotal of COPD. Expiratory flow shortcoming with changing disintegrates of the small airways compromises the capability of patients to expel air during expiration, sequencing in air trapping and lung hyperinflation. Acute-on-chronic hyperinflation has been revealed to render to difficulty of breathing during exercise and acute exaggeration in COPD. COPD is consociated with many comorbid situations. These involve IHD, osteopenia and osteoporosis, glaucoma and cataracts, cachexia and malnutrition, anemia, peripheral muscle malfunction, cancer and the metabolic syndrome. Rates of recognized anxiety and depression in COPD different from twenty percent to fifty percent and escalate with disease severity [13]. Smoking cigarette (and other irritants) activates macrophages in the respiratory tract that recognize neutrophil chemotactic agents, involving IL-8 and LTB4. These cells then recognize proteases that disintegrate connective tissue in the lung parenchyma, sequencing in emphysema, and also enliven mucus hyper production.



Figure 1: Inflammatory mechanisms in COPD.

Journal of
Biomedical and Biological Sciences

Review Article Open Access

These enzymes are usually restrained by protease inhibitors, involving 1-antitrypsin, SLPI, and TIMP. Cytotoxic T cells (CD8) perhaps recruited and perhaps included in alveolar wall decrement. Fibroblasts perhaps initiated by growth agents recognizes from macrophages and epithelial cells. CTG, connective tissue growth agent; COB, chronic obstructive bronchiolitis [14]. Systemic inflammation probably plays a key function in the advancement of these coincident disease states, and raised biomarkers such as C-reactive protein are consociated with an escalated peril of comorbidities. End-stage COPD is described by progressively worsening dyspnea during initiates of daily living, and ultimately even at rest. Furthermore symptoms, involving cough, difficulty in expectoration, loss of energy, tiredness, loss of weight, and insomnia, are often seen. Understandably, these patients also injured from anxiety, panic, and depression. Hospital admissions become consummate ubiquitous, and patients spend the left months of their lives at home, or with hospice care, gradually losing their independence. Amid end-stage COPD patients, factors such as recent cigarette smoke, comorbidities, low BMI, and hypoxemia are predictors of survival [15, 16].

Treatment

COPD is treatable at any stage of the illness. A treatment technique consisting of combined pharmacotherapy and non-pharmacotherapeutic interventions can effectively ameliorate symptoms, activity levels and QOL at all degrees of disease severity. The objectives of COPD treatment involve inhibition of disease advancement; decrement of the frequency and severity of exaggerations; relief of dyspnea and other respiratory symptoms; controlling exposure to peril factors, improvement of exercise tolerance; inhibit clinical manifestations and recurrent exacerbations and to preserve optimal lung function both in the short- and long-term; thus, ameliorating activity of daily living and accelerating the QOL, quick management of exacerbations and complications of the disease; recognizing and managing AEs, complications and co-morbid conditions, improvement of health status; and reduction of mortality [13].

Non-Pharmacological Management

Cessation of smoking: Smoking cessation slows the smoking-induced raised rate of decrement in lung function, ameliorates health and decreases mortality, irrespective of the serious of the pulmonary failure in patients with COPD. A large priority should be bestowed to the initial inhibition of COPD by decreasing the number of persons who starts to smoke. For patients who have already advanced COPD, smoking cessation decreases the rate of lung function decrement. Stopping smoking should be seen as a constant target and patients perhaps necessitated to be incentive to go through the cycle of contemplation of cessation, constructive action and relapse multiple times. Slow withdrawal perhaps successful in decreasing total tobacco consumption but is specifically unsuccessful in achieving cessation. Heavy smokers and those with many prior attempts are less probably to be successful. The initial stage is to render a description of the outcomes of smoking, and the advantages of cessation, and to contribute encouragement to stop. A minority of patients will cease smoking after few counseling, which perhaps further successful at the time of presentation with respiratory or distinctive symptoms. Counsel should involve useful strategies in ceasing and incentive on distinctive healthy life style alters. If such incentive is not successful, then the next or 2nd stage is further intensive assistance. This perhaps involves nicotine substituting, behavioural intervention, individual or group programmes. Impermanent nicotine replacements by chewing gum or transcutaneous routes and behavioural intervention have been revealed to escalate success rates. Patients aged greater than sixty-five years perhaps still gain up to four years of added life expectancy when they quit smoking [3, 17]. Varenicline recently is consociated with the greatest sustained abstinence rate and necessitates no dosage adjustment in the geriatrics.

Controlling occupational and atmospheric pollution: Occupational exposure to environmental pollution and to irritant dusts and fumes can trigger symptoms. Continued injury influences to enhanced decrement in FEV1 in patients with COPD. Protection of workers through masks and irritant dusts and fumes

Journal of
Biomedical and Biological Sciences
Bereda G, J. Biomed. Biol. Sci. 2022, 2:1
Review Article
Open Access

are released. Particular occupational pitfalls require to be regulated gingerly. High degrees of atmospheric pollution perhaps exacerbate symptoms and injury work of patients with COPD. Indoor and outdoor air quality can be ameliorated through compliance to air quality guidelines [5].

Education: Education of the patient and family with supervision and assist depending on disease-specific self-management techniques is significant. COPD education necessitates to be individualized and will different with disease severity. Particular educational interventions, such as self-treatment programs and smoking stopping advice, have been revealed to decrease health resource usage related to treatment of acute exacerbations. Elements of COPD education involve effective inhaler strategy, early recognition and management of acute exacerbations, distinguishing of community resources and end-of-life care issues [13].

Pharmacological Management

Pharmacotherapy for COPD involves bronchodilators, corticosteroids, anti-bacterial and combinations of these agents. The function of these agents is highly to ameliorate symptoms and exercise tolerance.



Figure 2: A comprehensive approach to the treatment of COPD. AECOPD: Acute exacerbation of COPD; LABA: Long-acting beta2-agonist; MRC: Medical Research Council; PRN: As needed; Rx: Treatment.

Short-acting bronchodilators, both anticholinergics and beta2-agonists, have been revealed to ameliorate pulmonary work, dyspnoea and exercise performance in patients with moderate to serious COPD. Selection of COPD management is depending on probably patient adherence, individual reaction, and side effects.

Bronchodilators

Bronchodilator medications relax smooth muscles in the airways. Although bronchodilators are the pivotal of symptom treatment in COPD, they have not been revealed to reduce mortality. The recommended route of delivery is by inhalation. The three chief categories of bronchodilators are the b-adrenergic receptor agonists, anticholinergics and the phosphodiesterase inhibitors, such as the methylxanthines. Clinical advantages of bronchodilators are de-escalated exercise capacity, reduced air trapping, and alleviate of symptoms such as dyspnoea. Short-acting agents are helpful in patients with mild, intermittent symptoms. Long-acting agents are preferred in patients with persistent symptoms, and are further effective in reducing dynamic hyperinflation, which is considered to play an indispensable function in dyspnoea [3].

Short Acting β2-Agonists

Inhalational Delivery Devices: Albuterol, levalbuterol, bitolterol, pirbuterol, and terbutaline are the recommended short-acting agents because it has higher β2 selectivity and prolong durations of action than other. Inhaled medications can be rendered by way of metered-dose inhalers (MDIs), dry powder inhalers (DPIs) or compressor nebulizers. . Many factors, such as user strategy, particle size and type of render device, influence the efficacy of inhaled drugs. In geriatric patients, inhalational technique is generally influenced by cognitive impairment and physical limitations. A large volume spacer (LVS) attached to an MDI reduces to require for coordinating device actuation and inhalation [3, 18, 19]. Appropriate patient education and assessment of inhalation technique should be an integral part of every visit of the COPD patient to the doctor [3, 5]. Inhaled beta2 agonists are well tolerated. Systemic effects (tachycardia, angina, & tremor) can

Journal of
Biomedical and Biological Sciences

Review Article Open Access

happen, but are ordinarily minimal. If dosage of oral preparations is excessive, stimulation of cardiac beta1 receptors can antecedent angina pectoris and Tachydysrhythmias. Patients should be instructed to narrate chest pain or alters in heart rate or rhythm. Tremor (by activating beta2 receptors in skeletal muscle) then tremor can be decreased by reducing the dosage or spontaneously.

Short-acting muscarinic antagonist (SAMA): By inhalation, blocks acetylcholine, with the net outcome being a decrement in cyclic guanosine monophosphate, which usually acts to constrict bronchial smooth muscle. Inhaled anticholinergic medications block the muscarinic receptors in the airways, hence obviating vagally mediated broncho motor tone and also effective in minimizing airway mucus secretion. Recently present agents involve the short acting ipratropium bromide [3, 20, 21]. Anticholinergic agents are further effective in COPD than in asthma. Ipratropium bromide has a slower onset of action than short-acting β2-agonists (15 to 20 m' vs. 5 m) and further extended bronchodilator outcome. Its peak outcome happens in 1.5 to 2 hrs and its duration is 4 to 6 hrs and 6–8 hrs for oxitropium. The preferred dose via MDI is 2 puffs 4 folds a day with upward titration frequently to 24puffs/day. Comparisons with β2-agonists based on the doses given [5].

Long Acting β2-Agonists

Long-acting beta-2 agonists: Regular management with long-acting bronchodilators is the cornerstone of therapy in symptomatic patients with moderate to severe COPD. Long-acting beta2-agonists (LABAs) (e.g., salmeterol 50 µg twice daily or formoterol 12 µg twice daily) offer further sustained improvements in pulmonary work, chronic dyspnoea and health status than SABAs in patients with moderate to severe COPD. However, the outcomes of LABAs on exercise performance have been not consistent [13]. Long-acting inhaled or oral β2-agonists provide an optional, particularly for patients with night-time or early morning symptoms. Notwithstanding, adequate surveys of long acting inhaled β2-agonists in COPD are not yet present [5].

Long-acting muscarinic antagonist (LAMA): The long-acting tiotropium bromide has 24-hr duration of action. Tiotropium bromide is superior to ipratropium bromide at standard doses and supports ameliorate lung function, symptoms, quality of life, frequency of exacerbations, hospitalizations and respiratory failure rates but has no impact on mortality or on the rate of decrement in lung function in patients with COPD [3, 20, 21]. Tiotropium renders improvements in lung hyperinflation, exercise endurance, exacerbations and health resource usage when analogized with placebo in patients with moderate to severe COPD. When analogized with LABAs, tiotropium gives more improvements in lung function and is consociated with larger improvements in dyspnoea and health status [13].

Combined long-acting bronchodilators: Combination of LAAC and LABA bronchodilators perhaps have additive sustained outcomes on pulmonary function in patients with moderate to severe COPD. At submaximal doses combinations of anticholinergics and β2-agonists will secrete an additive effect [5, 13]. Combining tiotropium bromides with a LABA perhaps generate more improvements in FEV1 and decrease to require for rescue inhalers greater than either agent alone. A combination of a SABA and a short acting anticholinergic agent secretes greater improvement in spirometry than either agent alone. The combination of an inhaled anticholinergic and β2-agonist is frequently used, generally as the disease progresses and symptoms worsen over time. Combining bronchodilators with distinctive mechanisms of action permits the low effective doses to be used and decreases adverse drug reactions from individual agents. A combination product containing albuterol and ipratropium (Combivent) is present as an MDI for chronic maintenance treatment of COPD [3].

Phosphodiesterase-4 inhibitors: Theophylline and aminophylline perhaps secrete bronchodilation by suppression of phosphodiesterase (cAMP levels), suppression of Ca^{2+} influx into smooth muscle, prostaglandin antagonism, enliven of endogenous catecholamines. Chronic theophylline usage in COPD has been revealed to secrete improvements in lung function, involving essential capacity and FEV1.

Journal of
Biomedical and Biological Sciences

Review Article Open Access

Subjectively, theophylline has been revealed to decrease dyspnoea, escalate exercise tolerance, and ameliorate respiratory drive. Methylxanthines are no longer thought-out 1st-line treatment because of theophylline's pitfalls. Theophylline is the further broadly used methylxanthine and causes bronchodilation initially through inhibition of phosphodiesterase. Theophylline has de novo anti-inflammatory outcomes and also reverses corticosteroid resistance, but the clinical significance of these outcomes is not obvious [3]. The role of theophylline in COPD is as maintenance therapy in non–acutely ill patients. In patients with COPD, the specific phosphodiesterase-4 inhibitor roflumilast significantly decreased the absolute number of neutrophils in sputum and the concentrations of CXCL8 and neutrophil elastase in sputum supernatants. This anti-inflammatory effect of roflumilast might identical with its decrement of exacerbations in serious COPD patients with chronic bronchitis symptoms and a history of COPD exacerbations [22, 23]. Oral theophylline is comparatively weak bronchodilators that give modest improvements in pulmonary function, dyspnoea and exercise performance. Benefits of theophylline require being weighed fight the peril of severe cardiovascular and neurological side effects. Drug interactions are ubiquitous and it is necessary to monitor medications levels with blood tests [13]. Theophylline is given orally, and aminophylline can be administered either PO or IV. These medications have analogized or least bronchodilator effects than β2-agonists or anticholinergic agents. Methylxanthines have distinctive consequences, such as systemic and pulmonary vascular dilatation, escalated salt and water excretion, and CNS stimulation. There is also an outcome on respiratory muscles, but this is improbably to be important at normal therapeutic levels. Adverse drug reactions involve gastric irritation, nausea, diarrhoea, headache, tremor, irritability, sleep disturbance, epileptic seizures, and cardiac arrhythmias [5]. Treatment can be initiated at 200 mg twice daily and titrated upward every three to five days to the target dose; most patients need daily doses of 400 to 900 mg. Dose adjustments should particularly be made depending on trough serum concentration results. A conservative therapeutic range of 8 to 15mcg/mL is frequently targeted, generally in geriatric patients, to decrease the likelihood of toxicity. The adverse effects of theophylline involve gastrointestinal symptoms such as nausea and vomiting at primary oral administration. Furthermore, toxic symptoms perhaps progress to tachycardia and arrhythmia. In the consummate serious cases, convulsions perhaps happen that can influence to death.

Inhaled corticosteroids (ICS) alone: Corticosteroids de-escalate in capillary permeability to reduce mucus, suppression of recognize of proteolytic enzymes from leukocytes, and suppression of prostaglandins. ICS do not have similar effects on indices of airway inflammation, pulmonary function, symptoms, frequency or severity of exacerbation, and health status in COPD. ICS alone is particularly inferior to an ICS/LABA combination for entire of the above consequences [5]. ICSs are present as DPIs, MDIs or as formulations that can be nebulized. A variety of studies revealed that ICSs ameliorate lung function and symptoms, and de-escalate airway reactivity and frequency of exacerbations [3, 24, 25]. The function of inhaled corticosteroids, which have the merit of secreting no or fewer systemic adverse drug reactions than oral corticosteroids, is much debated. Short-term surveys revealed no or marginal beneficial effects on symptoms, lung function, and hyperresponsiveness. Adverse drug reactions of inhaled glucocorticoids: These preparations are highly devoid of severe toxicity, even when used in much doses. The consummate ubiquitous adverse drug reactions are oro-pharyngeal candidiasis and dysphonia (hoarseness, speaking difficulty). Both effects sequence from local deposition of inhaled glucocorticoids. To decrease these effects, patients should; i) gargle after each administration and ii) employ a spacer device during administration, which will greatly decrease drug deposition in the oropharynx. If candidiasis advances, it can manage with antifungal medications. With long-term, high-dose therapy, certain adrenal suppression perhaps advance, although the level of suppression is particularly low. In contrary, with prolonged usage of oral glucocorticoids, adrenal suppression can be predominant. Can also enhance bone loss at least in premenopausal women, but much lower than oral glucocorticoids. To decrease bone loss,

Journal of
Biomedical and Biological Sciences

Review Article Open Access

patients should; i) use the lowest dose possible, ii) guarantee adequate intake of calcium and vitamin D, and iii) participate in weight-bearing exercise. Glucocorticoids can slow growth in paediatric and adolescents but do not decrease adult height.

ICS/LABA combinations: Combination of inhaled corticosteroids and long-acting bronchodilators has additive effect. Salmeterol plus fluticasone or formoterol plus budesonide are highly improvements in FEV1, health status, and exacerbation of COPD. Management with ICS/LABA ameliorated 2^{ndry} effect measures (exacerbation decrement, improvement of pulmonary function and health status) in comparison with placebo, LABA and ICS alone [13]**.** Combinations of LABAs and ICSs are very popular because of the presence of combination formulations and render devices. Such combinations have been revealed to ameliorate symptoms, lung function and QOL, de-escalate AEs and even reduce the rate of decrement in FEV1, but have no outcome on mortality [3, 26, 27].

Triple therapy: Lung function seems to ameliorate when ICSs are added to the combination of a LABA and tiotropium bromide ('triple therapy'), but the choice of the LABA used appears to influence the sequences. Triple therapies perhaps reduce overall hospital admissions. Improvement in lung function has been similarly narrated with triple therapy analogized with LAMA or LABA/ICS alone [3, 28, 2].

Systemic Corticosteroids: Oral or systemic medications are used empirically during exacerbations and are frequently of benefit. Long-term systemic corticosteroids are consociated with important adverse effects, such as myopathy, osteoporosis, vertebral and hip fractures, glucose intolerance and cataract formation. Such therapy is not preferred for the long-term management of COPD [3]. Adverse drug reactions involve adrenal suppression, osteoporosis, hyperglycaemia, peptic ulcer disease, and, in young patients, suppression of growth.

Mucolytic and antioxidant agents: In COPD, mucus is particularly oodles and tenacious, properties considered to enhance infection and lung injury. If this is so, ameliorated sputum clearance might reduce as symptoms and the loss of lung function. Two types of medications are used: mucolytics, which contain substances that accelerate disintegration of mucoproteins; and mucoregulators, which decrease viscosity by changing sialomucin synthesis. These medications are bestowed orally or parenterally; acetylcysteine and ambroxol can also be given by nebulization [5].

Respiratory stimulants: Oral almitrine bismesylate can ameliorate oxygen tension to an identical degree as does a small escalate in inspired oxygen. At the doses used usually, multiple adverse drug reactions occurred, specifically peripheral neuropathy [5].

Antimicrobial therapy: Antibiotics are of consummate benefit and should be induced if at least 2 of the following 3 symptoms are available when escalated dyspnoea; escalated sputum volume; and escalated sputum purulence. Selection of empiric antimicrobial therapy should be depending on the consummate probably organisms. Antibacterial is further helpful in the management of AEs, particularly in patients who available with escalated sputum purulence. In sicker patients with moderate to serious exacerbations, antibacterial de-escalate mortality, duration of mechanical ventilation and the length of hospital stay. Shorter courses of antibacterial (£5 days) are as effective as longer courses [3, 30, 31]**.** Pathogens perhaps sophisticated to distinguish in exacerbations of COPD. The consummate ubiquitous organisms are Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and viruses. Therapy should be induced within twenty-four hours of symptoms to inhibit unneeded hospitalization and particularly given for at least seven to ten days. Cheap antibiotics are adequate in further cases. Ubiquitously used antibiotics are amoxycillin, tetracycline derivatives, and amoxycillin/clavulanic acid. Optional treatments involve newer cephalosporins, macrolides, and quinolone antibiotics. Trimethoprim-sulfamethoxazole, Amoxicillin, first generation cephalosporins, erythromycin is not recommended because resistance. Amoxicillin/ clavulanate or a fluoroquinolone with accelerated pneumococcal activity (levofloxacin, gemifloxacin, moxifloxacin) are used in complicated

Journal of
Biomedical and Biological Sciences

Review Article Open Access

exacerbations of COPD where drug-resistant pneumococci, β-lactamase- producing H. influenzae and M. catarrhalis, and certain enteric gram-negative organisms perhaps available. In complicated exacerbations with peril of Pseudomonas aeruginosa, preferred management involves a fluoroquinolone with enhanced pneumococcal and P. aeruginosa activity (levofloxacin). If IV therapy is needed, β-lactamase resistant penicillin with antipseudomonal activity or a third- or fourth-generation cephalosporin with antipseudomonal activity should be used. Macrolides have anti-inflammatory actions furthermore to their antibacterial actions, and are effective in reducing exacerbations and ameliorating lung function in diseases such as cystic fibrosis and diffuse pan bronchiolitis [3, 32, 33]**.** In this COPD sub phenotype, long-term macrolide treatment was consociated with important decrement in the rate of exacerbations analogized with placebo. Low dose macrolide treatment revealed much the identical benefits in distinctive chronic neutrophilic airway diseases, involving diff use pan bronchiolitis, bronchiolitis obliterans syndrome after lung trans plantation, cystic fibrosis, and non-cystic fibrosis bronchiectasis. The anti-inflammatory mechanisms of macrolides require to be totally explained, but probably enclose pleiotropic inhibitory outcomes on neutrophil elastase, interleukin 17 secretions by T lymphocytes and CXCL8 and GM-CSF release from epithelial cells, and upregulation of the expression of the mannose receptor on alveolar macrophages, which ameliorates the phagocytosis of apoptotic cells. The occurrences of Staphylococcus, resistant Haemophilus, and Streptococcus infections in exacerbations of COPD are escalating. Cultures of sputum in exacerbations supports ascertain proper second choices of therapy when reaction to initial therapy is poor [34, 35].

Oxygen therapy: Oxygen therapy is used for any patient with hypoxemia. Should be used to achieve a partial oxygen of more than 60 mm Hg or SaO_2 of more than 90% and arterial blood gases should be acquired after oxygen induction to monitor carbon dioxide retention sequencing from hypoventilation. Long-term oxygen therapy (LTOT) for at least 15 hrs per day is recommended in the following situations: (i) PaO2 £55 mmHg on room air; (ii) SaO2 in arterial blood (SaO2) 55% [36]**.** Long-term continuous oxygen (15 h/day or further to achieve an oxygen saturation of 90% or greater) offers a survival merit to patients with stable COPD with serious hypoxemia (partial pressure of arterial oxygen 55 mmHg or less), or when partial pressure of arterial oxygen is less than 60 mmHg in the availability of bilateral ankle oedema, corpulmonale or a haematocrit of more than 56% [13].

Conclusion

COPD is a growing global epidemic that is generally significant in developing countries. Morbidity and mortality from COPD will accelerated as population's age and mortality from CV and infectious diseases falls. Exposure to tobacco smoke is by far the consummate significant peril factor for COPD, and the intensity and duration of exposure correlate with the severity of failures. Indoor air pollution from biomass fuels and wood burning are also implicated in causing COPD, specifically in women in developing countries. Systemic inflammation likely plays a pivotal function in the advancement of these coincident disease states, and raised biomarkers such as C-reactive protein are consociated with an escalated peril of comorbidities. Long-acting inhaled or oral β2-agonists give an optional, generally for patients with night-time or early morning symptoms. However, sufficient surveys of long acting inhaled β2-agonists in COPD are not yet present.

Acknowledgement

The author acknowledged those who support him during preparation of this manuscript.

Data Sources: Sources searched include Google Scholar, Research Gate, PubMed, NCBI, NDSS, PMID, EMBASE, Science direct, Sceilo, PMCID, Scopus database and Cochrane database. Search terms included: definition, risk factors, pathophysiology and management of chronic obstructive pulmonary disease.

Journal of
Biomedical and Biological Sciences

Review Article Open Access

References

1. Charriot J, Volpato M, Petit A, Vachier I, Bourdin A. Methods of Sputum and Mucus Assessment for Muco-Obstructive Lung Diseases in 2022: Time to "Unplug" from Our Daily Routine! Cells. 2022 Feb 25;11(5):812.

2. Okuda K, Chen G, Subramani DB, Wolf M, Gilmore RC, Kato T, Radicioni G, Kesimer M, Chua M, Dang H, Livraghi-Butrico A. Localization of secretory mucins MUC5AC and MUC5B in normal/healthy human airways. American journal of respiratory and critical care medicine. 2019 Mar 15;199(6):715-27.

3. Lynch DA, Moore CM, Wilson C, Nevrekar D, Jennermann T, Humphries SM, Austin JH, Grenier PA, Kauczor HU, Han MK, Regan EA. CT-based visual classification of emphysema: association with mortality in the COPDGene study. Radiology. 2018 Sep;288(3):859-66.

4. Wan ES, Fortis S, Regan EA, Hokanson J, Han MK, Casaburi R, Make BJ, Crapo JD, DeMeo DL, Silverman EK. Longitudinal phenotypes and mortality in preserved ratio impaired spirometry in the COPDGene study. American journal of respiratory and critical care medicine. 2018 Dec 1;198(11):1397-405.

5. Ostridge K, Gove K, Paas KH, Burke H, Freeman A, Harden S, Kirby M, Peterson S, Sieren J, McCrae C, Vaarala O. Using novel computed tomography analysis to describe the contribution and distribution of emphysema and small airways disease in chronic obstructive pulmonary disease. Annals of the American Thoracic Society. 2019 Aug;16(8):990-7.

6. Wang K, Mamidipalli A, Retson T, Bahrami N, Hasenstab K, Blansit K, Bass E, Delgado T, Cunha G, Middleton MS, Loomba R. Automated CT and MRI liver segmentation and biometry using a generalized convolutional neural network. Radiology: Artificial Intelligence. 2019 Mar 27;1(2):180022.

7. Blansit K, Retson T, Masutani E, Bahrami N, Hsiao A. Deep learning–based prescription of cardiac MRI planes. Radiol Artif Intell. 2019; 1: e180069.

8. Bahrami N, Retson T, Blansit K, Wang K, Hsiao A. Automated selection of myocardial inversion time with a convolutional neural network: Spatial temporal ensemble myocardium inversion network (STEMI-NET). Magnetic resonance in medicine. 2019 May;81(5):3283-91.

9. Humphries SM, Notary AM, Centeno JP, Strand MJ, Crapo JD, Silverman EK, Lynch DA, Genetic Epidemiology of COPD (COPDGene) Investigators. Deep learning enables automatic classification of emphysema pattern at CT. Radiology. 2020 Feb;294(2):434-44.

10. Gerard SE, Patton TJ, Christensen GE, Bayouth JE, Reinhardt JM. FissureNet: a deep learning approach for pulmonary fissure detection in CT images. IEEE transactions on medical imaging. 2018 Aug 10;38(1):156-66.

11. Park B, Park H, Lee SM, Seo JB, Kim N. Lung segmentation on HRCT and volumetric CT for diffuse interstitial lung disease using deep convolutional neural networks. Journal of digital imaging. 2019 Dec;32(6):1019-26.

12. Gerard SE, Herrmann J, Kaczka DW, Musch G, Fernandez-Bustamante A, Reinhardt JM. Multi-resolution convolutional neural networks for fully automated segmentation of acutely injured lungs in multiple species. Medical image analysis. 2020 Feb 1; 60:101592.

Journal of
Biomedical and Biological Sciences

Review Article Open Access

13. Park J, Yun J, Kim N, Park B, Cho Y, Park HJ, Song M, Lee M, Seo JB. Fully automated lung lobe segmentation in volumetric chest CT with 3D U-Net: validation with intra-and extra-datasets. Journal of digital imaging. 2020 Feb;33(1):221-30.

14. Kirby M, Hatt C, Obuchowski N, Humphries SM, Sieren J, Lynch DA, Fain SB, QIBA Lung Density Committee. Inter-and intra-software reproducibility of computed tomography lung density measurements. Medical Physics. 2020 Jul;47(7):2962-9.

15. González G, Ash SY, Vegas-Sánchez-Ferrero G, Onieva Onieva J, Rahaghi FN, Ross JC, Diaz A, San José Estépar R, Washko GR. Disease staging and prognosis in smokers using deep learning in chest computed tomography. American journal of respiratory and critical care medicine. 2018 Jan 15;197(2):193-203.

16. Celli BR, Wedzicha JA. Update on clinical aspects of chronic obstructive pulmonary disease. New England Journal of Medicine. 2019 Sep 26;381(13):1257-66.

17. Kunisaki KM, Dransfield MT, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, Hartley BF, Martinez FJ, Newby DE, Pragman AA. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. American journal of respiratory and critical care medicine. 2018 Jul 1;198(1):51-7.

18. Divo M, Celli BR. Multimorbidity in patients with chronic obstructive pulmonary disease. Clinics in Chest Medicine. 2020 Sep 1;41(3):405-19.

19. Barbosa-Lorenzo R, Ruano-Ravina A, Fernández-Villar A, López-Pardo E, Carballeira-Roca C, Barros-Dios JM. COPD prevalence and hospital admissions in Galicia (Spain). An analysis using the potential of new health information systems. Pulmonology. 2018 Nov 1;24(6):323-9.

20. Noell G, Cosío BG, Faner R, Monsó E, Peces-Barba G, de Diego A, Esteban C, Gea J, Rodriguez-Roisin R, Garcia-Nuñez M, Pozo-Rodriguez F. Multi-level differential network analysis of COPD exacerbations. European Respiratory Journal. 2017 Sep 1;50(3).

21. Tseng CY, Chang JC, Chen YC, Huang HH, Lin CS, How CK, Yen DH. Changes of heart rate variability predicting patients with acute exacerbation of chronic obstructive pulmonary disease requiring hospitalization after Emergency Department treatment. Journal of the Chinese Medical Association. 2018 Jan 1;81(1):47-52.

22. Rubio N, Parker RA, Drost EM, Pinnock H, Weir CJ, Hanley J, Mantoani LC, MacNee W, McKinstry B, Rabinovich RA. Home monitoring of breathing rate in people with chronic obstructive pulmonary disease: observational study of feasibility, acceptability, and change after exacerbation. International Journal of Chronic Obstructive Pulmonary Disease. 2017; 12:1221.

23. Elvekjaer M, Aasvang EK, Olsen RM, Sørensen HB, Porsbjerg CM, Jensen JU, Haahr-Raunkjaer C, Meyhoff CS. Physiological abnormalities in patients admitted with acute exacerbation of COPD: an observational study with continuous monitoring. Journal of clinical monitoring and computing. 2020 Oct;34(5):1051-60.

24. Osadnik CR, Tee VS, Carson-Chahhoud KV, Picot J, Wedzicha JA, Smith BJ. Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2017(7).

25. O'Driscoll BR, Howard LS, Earis J, Mak V. British thoracic society emergency oxygen guideline group; BTS emergency oxygen guideline development group. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017;72(Suppl 1): ii1-90.

Journal of
Biomedical and Biological Sciences

Review Article Open Access

26. Al Rajeh AM, Hurst JR. Monitoring of physiological parameters to predict exacerbations of chronic obstructive pulmonary disease (COPD): a systematic review. Journal of clinical medicine. 2016 Dec;5(12):108.

27. Al Rajeh AM, Aldabayan YS, Aldhahir A, Pickett E, Quaderi S, Alqahtani JS, Mandal S, Lipman MC, Hurst JR. Once daily versus overnight and symptom versus physiological monitoring to detect exacerbations of chronic obstructive pulmonary disease: pilot randomized controlled trial. JMIR mHealth and uHealth. 2020 Nov 13;8(11): e17597.

28. Nunez A, Marras V, Harlander M, Mekov E, Esquinas C, Turel M, Lestan D, Petkov R, Yanev N, Pirina P, Negri S. Association between routine blood biomarkers and clinical phenotypes and exacerbations in chronic obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease. 2020; 15:681.

29. Andelid K, Andersson A, Yoshihara S, Åhrén C, Jirholt P, Ekberg-Jansson A, Linden A. Systemic signs of neutrophil mobilization during clinically stable periods and during exacerbations in smokers with obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease. 2015; 10:1253.

30. Leuzzi G, Galeone C, Taverna F, Suatoni P, Morelli D, Pastorino U. C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis. European Respiratory Review. 2017 Mar 31;26(143).

31. Butler CC, Gillespie D, White P, Bates J, Lowe R, Thomas-Jones E, Wootton M, Hood K, Phillips R, Melbye H, Llor C. C-reactive protein testing to guide antibiotic prescribing for COPD exacerbations. New England Journal of Medicine. 2019 Jul 11;381(2):111-20.

32. Couturaud F, Bertoletti L, Pastre J, Roy PM, Le Mao R, Gagnadoux F, Paleiron N, Schmidt J, Sanchez O, De Magalhaes E, Kamara M. Prevalence of pulmonary embolism among patients with COPD hospitalized with acutely worsening respiratory symptoms. Jama. 2021 Jan 5;325(1):59-68.

33. Aleva FE, Voets LW, Simons SO, de Mast Q, van der Ven AJ, Heijdra YF. Prevalence and localization of pulmonary embolism in unexplained acute exacerbations of COPD: a systematic review and meta-analysis. Chest. 2017 Mar 1;151(3):544-54.

34. Hiles SA, Gibson PG, Agusti A, McDonald VM. Treatable traits that predict health status and treatment response in airway disease. The Journal of Allergy and Clinical Immunology: In Practice. 2021 Mar 1;9(3):1255-64.

35. Scarlata S, Finamore P, Laudisio A, Cardaci V, Ramaccia M, D'Alessandro F, Pedone C, Antonelli Incalzi R, Cesari M. Association between frailty index, lung function, and major clinical determinants in chronic obstructive pulmonary disease. Aging clinical and experimental research. 2021 Aug;33(8):2165-73.

36. Balte PP, Chaves PH, Couper DJ, Enright P, Jacobs DR, Kalhan R, Kronmal RA, Loehr LR, London SJ, Newman AB, O'Connor GT. Association of nonobstructive chronic bronchitis with respiratory health outcomes in adults. JAMA internal medicine. 2020 May 1;180(5):676-86.